Objective: To explore the relationship between the expression of placental growth factor (PLGF) and Zeste homolog enhancer 2 (EZH2) in placental tissues of women with gestational diabetes (GDM), placental function, and pregnancy outcome.
Methods: Select 100 women with GDM diagnosed in our hospital from January 2019 to May 2020 as the GDM group and 100 women with normal pregnancy at the same time as the control group. Detection and analysis of the expression levels of PLGF and EZH2 proteins in placental tissue after delivery of the two components. Observation of the expression of different PLGF and EZH2 proteins using an electron microscope, and analyze the ultrastructural changes in placental tissue of women with GDM. Finally, assess the differences in pregnancy outcomes.
Results: The expression intensity of PLGF protein in the GDM group was higher than that in the control group (P < .001), and the expression intensity of EZH2 protein in the GDM group was lower than that in the control group (P < .001); the positive rate of PLGF protein in the GDM group was 67.00% higher than that of the control group 35.00% (P < .001), the positive rate of EZH2 protein in the GDM group was 15.00% lower than 33.00% in the control group (P = .003); the placental ultrastructural change rate of PLGF-positive GDM women was 71.64% higher than that in the negative expression group 45.45 % (P = .011); the placental ultrastructural change rate of EZH2 protein-positive GDM mothers was 33.33% lower than that of negative expression of A mixed 68.24% (P = .01); the incidence of premature infants (26.87%) and fetal respiratory distress (13.43%) in the PLGF-positive GDM group, the rate was higher than that in the negative expression group (9.09%, 0%) (P = .027, .04); the incidence of preterm infants in the EZH2 protein-positive GDM group (0.00%) was lower than that in the negative expression group (24.71%) (P = .03).
Conclusion: The expression of PLGF is up-regulated and the expression of EZH2 is down-regulated in the placental tissue of GDM women, which causes ultrastructural changes in the placental tissue and increases the incidence of preterm birth and fetal respiratory distress to a certain extent.